How Much Does Belsomra (Suvorexant) Cost in District of Columbia?

Belsomra Retail Pricing in DC: What You Actually Pay

The gap between Merck's wholesale acquisition cost and what DC residents pay at the counter is significant. Merck lists Belsomra at $340 per month, but the average cash-pay price across District of Columbia retail pharmacies in 2026 sits near $85 per month for a 30-tablet supply. That price can vary by $20 to $40 depending on the pharmacy. Independent pharmacies in neighborhoods like Adams Morgan or Anacostia sometimes price below chains, while pharmacies near downtown corridors trend higher.

Suvorexant works by blocking orexin receptors, the neuropeptides that promote wakefulness. A key trial by Herring et al. (2014, N=3,000) in The Lancet Neurology demonstrated that suvorexant at doses of 20 mg and 40 mg significantly improved subjective total sleep time by approximately 20 to 25 minutes versus placebo over four weeks. The 20 mg dose reduced wake-after-sleep-onset by a median of 22.4 minutes compared to placebo at month one. These outcomes led to FDA approval in August 2014, with recommended doses of 10 mg (starting) and 20 mg (maximum).

Dr. Emmanuel Mignot, professor of sleep medicine at Stanford University, has noted: "Orexin receptor antagonists represent a mechanistic departure from traditional sedative-hypnotics because they target the specific arousal pathway rather than broadly depressing the central nervous system." That distinction matters for cost discussions because Belsomra occupies a therapeutic niche with no generic equivalent and limited direct competitors, which keeps prices elevated even at retail discount.

DC Medicaid Coverage for Belsomra

District of Columbia Medicaid covers Belsomra, but requires prior authorization (PA). The PA process involves demonstrating that the patient has tried and failed at least one formulary-preferred sleep agent, typically a generic sedative-hypnotic such as zolpidem or trazodone. DC's Medicaid managed care organizations (MCOs), including AmeriHealth Caritas DC and CareFirst Community Health Plan, each maintain their own PA forms and turnaround windows.

Expect the PA process to take 24 to 72 hours in most cases. Prescribers must document the patient's insomnia diagnosis (ICD-10 G47.00 or G47.01), previous medication trials, and the clinical rationale for choosing a dual orexin receptor antagonist over formulary alternatives. Denial rates for Belsomra PA requests in Medicaid plans nationally run between 15% and 30% on initial submission, according to pharmacy benefit manager data.

A key consideration: Medicaid recipients who receive a denial have the right to appeal under DC's fair hearing process. The American Academy of Family Physicians (AAFP) guidelines on insomnia management support orexin receptor antagonists as second-line pharmacotherapy after cognitive behavioral therapy for insomnia (CBT-I) and first-line medications have been inadequate, which strengthens appeal arguments when clinical documentation is thorough.

If PA is denied and the appeal is unsuccessful, trazodone (generic, approximately $4 to $10 per month) and generic zolpidem ($8 to $15 per month) remain available without PA on most DC Medicaid formularies. These are pharmacologically different drugs, and the clinical trade-offs should guide the conversation between patient and prescriber.

Commercial Insurance and Belsomra Tier Placement in DC

Most commercial insurance plans available in DC place Belsomra on Tier 3 (preferred brand) or Tier 4 (non-preferred brand). That translates to copays typically between $40 and $75 per month, depending on the plan's benefit design. CareFirst BlueCross BlueShield, the dominant commercial insurer in the District, has historically placed Belsomra on Tier 3 with a step-therapy requirement.

Plans purchased through DC Health Link, the District's ACA marketplace, follow similar tiering. Silver and Gold plans generally carry lower brand-drug copays than Bronze plans, where coinsurance of 30% to 50% on Tier 3 drugs could push the out-of-pocket cost above cash-pay pricing. This creates an important decision point: residents on high-deductible Bronze plans may pay less using a discount card at a retail pharmacy than running Belsomra through insurance before the deductible is met.

The federal employees and military population in DC is substantial. TRICARE covers Belsomra on its formulary with PA requirements similar to Medicaid. Federal Employees Health Benefits (FEHB) plans vary, but most major options (BCBS FEP, GEHA, Kaiser Mid-Atlantic) include Belsomra with step therapy. Active-duty military personnel and retirees filling at a military treatment facility pharmacy pay $0 for formulary medications, which makes Belsomra free at facilities like Walter Reed if it appears on the MTF formulary.

According to a systematic review published in the Annals of Internal Medicine, dual orexin receptor antagonists demonstrate efficacy for both sleep-onset and sleep-maintenance insomnia, which supports formulary inclusion arguments when insurers require clinical justification beyond step-therapy failures.

Merck Savings Card: How It Works in DC

Merck offers a manufacturer savings card for commercially insured patients that can reduce the Belsomra copay to as little as $0, with a maximum annual benefit typically capped at $3,400. Eligibility requires commercial or private insurance. Patients covered by Medicare, Medicaid, TRICARE, or any other federal or state healthcare program do not qualify.

To activate the card, patients register at the Belsomra savings program website or receive a card from their prescriber's office. The card functions as a secondary payer at the pharmacy counter, covering the difference between the patient's copay and the program's minimum (often $0 to $10). Important: the card does not reduce the drug's list price. It reimburses the pharmacy for the patient's copay, which means it does not count toward the patient's insurance deductible in most plan designs.

DC residents should verify whether their specific commercial plan allows copay cards to apply. Some plans, particularly those with copay accumulator or copay maximizer programs, prevent manufacturer card payments from counting toward the annual out-of-pocket maximum. CareFirst and Aetna plans in the DC market have adopted accumulator provisions in select plan designs since 2023, which means patients could face full-price exposure after the savings card's annual cap is exhausted.

Compounded Suvorexant in District of Columbia

Compounded suvorexant is available through licensed 503A compounding pharmacies in the District of Columbia. Section 503A of the Federal Food, Drug, and Cosmetic Act permits state-licensed pharmacies to compound medications based on individual patient prescriptions when a clinical need exists, such as a patient requiring a dose not commercially available (for example, 7.5 mg) or an alternative dosage form like a sublingual troche.

A few points of clarification on cost claims. While some sources cite compounded suvorexant at $0 per month, that figure does not reflect typical patient experience. Compounding pharmacies charge for preparation, and prices vary based on the specific formulation, dose, and pharmacy. Realistic pricing for compounded suvorexant from a 503A pharmacy in DC ranges from $30 to $60 per month, which may still undercut the retail brand-name price.

The DC Board of Pharmacy regulates compounding pharmacies within the District. Pharmacies must hold a valid DC compounding license and comply with USP <795> standards for non-sterile compounding. Suvorexant is not on the FDA's "difficult to compound" list as of May 2026, which means 503A pharmacies may compound it without restriction provided they have a patient-specific prescription.

One clinical caution: compounded formulations do not undergo the same bioequivalence testing as FDA-approved products. The FDA has emphasized that compounded drugs are not FDA-approved and may differ in absorption, stability, or potency from manufactured products. Prescribers and patients should discuss these trade-offs, particularly for a drug like suvorexant where precise dosing affects next-morning residual sedation risk.

Telehealth Prescribing of Belsomra in DC

Telehealth prescribing of Belsomra is permitted in the District of Columbia. DC's telehealth regulations, updated during and after the COVID-19 public health emergency, allow prescribers to evaluate patients and write prescriptions for Schedule IV controlled substances (suvorexant is Schedule IV) via audio-visual telehealth visits. A DEA-registered prescriber with an active DC license can prescribe Belsomra after conducting an appropriate clinical evaluation remotely.

The practical advantage for DC residents: telehealth eliminates the need to visit a sleep specialist's office in person, which matters in a city where wait times for sleep medicine appointments at institutions like MedStar Georgetown or GW can stretch four to eight weeks. Several nationwide telehealth platforms prescribe sleep medications including suvorexant, and some DC-based concierge practices offer same-week virtual consultations.

Telehealth prescriptions for Belsomra can be sent electronically to any DC pharmacy. The American Academy of Sleep Medicine (AASM) has endorsed telehealth for insomnia management, noting that diagnostic evaluation and follow-up for uncomplicated insomnia disorder can be effectively conducted remotely, particularly when combined with CBT-I delivered through digital platforms.

How to Minimize Your Belsomra Cost in DC

Price variation across DC pharmacies is real. A 2024 analysis of GoodRx and RxSaver data showed that Belsomra 10 mg (30 tablets) ranged from $71 to $118 across DC retail pharmacies, a $47 spread within the same city. Checking prices at Costco (which does not require a membership for pharmacy services in DC), Amazon Pharmacy, and Mark Cuban's Cost Plus Drugs is a reasonable starting point.

A step-by-step approach to minimizing cost:

1. Ask your prescriber to check your insurer's formulary status and PA requirements before writing the prescription.
2. If commercially insured, activate the Merck savings card before your first fill.
3. Compare cash-pay prices across at least three pharmacies using a discount aggregator.
4. If your out-of-pocket cost exceeds $60 per month, ask your prescriber whether compounded suvorexant from a licensed 503A pharmacy is clinically appropriate.
5. If you are on DC Medicaid and receive a PA denial, file an appeal with supporting documentation from your prescriber that references your history of failed first-line agents.

The Endocrine Society clinical practice guidelines and the AASM together support the position that cost should not be the sole barrier to effective insomnia treatment, particularly when sleep disruption contributes to metabolic, cardiovascular, and mental health comorbidities. A meta-analysis in The BMJ (2022) found that DORAs, including suvorexant, had a number needed to treat (NNT) of 7 for clinically meaningful improvement in sleep onset and maintenance, comparable to Z-drugs but with a lower risk of next-day impairment at approved doses.

Suvorexant vs. Alternatives: DC Cost Comparison

Understanding where Belsomra fits in the pricing hierarchy helps DC residents make informed decisions with their prescribers.

Generic zolpidem (Ambien) runs $8 to $15 per month at DC pharmacies and remains the most prescribed sleep medication nationally. It works through a different mechanism (GABA-A receptor modulation) and carries higher risk of complex sleep behaviors, parasomnias, and next-day impairment, particularly at the 10 mg dose. The FDA issued a boxed warning in 2019 for serious injury risk from complex sleep behaviors with Z-drugs.

Generic trazodone costs $4 to $10 per month. It is prescribed off-label for insomnia and carries a different side-effect profile, including orthostatic hypotension and, rarely, priapism. No head-to-head trial has directly compared suvorexant to trazodone for insomnia outcomes.

Lemborexant (Dayvigo), the other FDA-approved DORA, carries a list price of approximately $380 per month and averages $90 to $110 at DC retail. A phase 3 trial (SUNRISE-2, N=949) demonstrated that lemborexant 5 mg and 10 mg improved subjective sleep-onset latency and wake-after-sleep-onset versus placebo at six months, with a safety profile comparable to suvorexant.

Quviviq (daridorexant), the newest DORA approved in 2022, lists at approximately $450 per month. Its distinguishing feature is a shorter half-life (8 hours vs. 12 hours for suvorexant), which may reduce next-morning residual effects. Retail pricing in DC averages $100 to $130 per month.

For DC residents whose primary concern is cost and whose insomnia responds to first-line agents, generic zolpidem or trazodone at under $15 per month is the most economical path. For those who need a DORA specifically, Belsomra at $85 average retail (or less with a savings card or compounding) is the lowest-cost branded option in the class.